PC
AGIO icon

Polar Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Polar Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-150,000
Closed -$8.02M – 299
2020
Q2 		$8.02M Buy
+150,000
New +$6.95M 0.07% 186
2019
Q2 		– Sell
-225,161
Closed -$15.2M – 284
2019
Q1 		$15.2M Sell
225,161
-109,839
-33% -$6.4M 0.14% 163
2018
Q4 		$15.4M Sell
335,000
-267,342
-44% -$16.5M 0.17% 149
2018
Q3 		$46.5M Buy
602,342
+137,342
+30% +$11M 0.4% 81
2018
Q2 		$39.2K Buy
+465,000
New +$40.6M 0.24% 97

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital's AGIO Position: Q3 2020 in Review

Polar Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2020, closing a stake of 150,000 shares — an estimated $8.02M sold.

Polar Capital first reported a position in AGIO in Q2 2018 and held it in 5 quarters. The position peaked at $46.5M in Q3 2018. 214 funds tracked by Wall St. Rank hold AGIO as of Q3 2020.

  • Polar Capital reported no remaining Agios Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Polar Capital sold 150,000 Agios Pharmaceuticals shares in Q3 2020, an estimated $8.02M.
  • Polar Capital first reported a position in Agios Pharmaceuticals in Q2 2018 and held it in 5 quarters.
  • Polar Capital's Agios Pharmaceuticals position peaked at $46.5M in Q3 2018.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.